Department of Orthopedics, the Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China.
Bosn J Basic Med Sci. 2011 May;11(2):80-3. doi: 10.17305/bjbms.2011.2585.
The aim of this article was to investigate the correlation between expression of O(6)-methylguanine-DNA methyltransferase (MGMT) in osteosarcoma and the curative effect of alkylating agent (Cis-diaminodichloroplatinum, CDDP). 42 male patients and 34 female patients with a median age of 17 years (9 to 43 years) were eligible for this study. According to histopathological types, there were 3 cases of telangiectatic osteogenic sarcoma, 22 cases of osteoblastic, 11 cases of chondroblastic and 16 cases of fibroblastic sarcoma. Immunohistochemical method was used to detect the expression of MGMT protein. The correlations between MGMT expression and the curative effect of CDDP on osteosarcoma have been investigated. It was shown by immunohistochemical staining that among 76 osteosarcoma biopsy specimens, 52 (68%) cases were positive, 27 (35%) cases were weak positive, 18 (24%), cases were moderate positive, and 7 (9%) cases were strong positive. There were no significant differences in MGMT expression among different pathological types of tumors (p>0.5). After CDDP chemotherapy, among pathologic specimens in which MGMT expression was positive, necrosis rates were as follows: grade I, 5 cases (38%); grade II, 7 cases (25%); grade III, 15 cases (21%); grade IV, 2 cases (23%). Osteosarcoma necrosis rate was low when the expression of MGMT protein was positive, whereas necrosis rate was high when there was a low level of MGMT expression (p<0.01). There was a significant negative correlation between the level of MGMT expression in osteosarcoma tissue and osteosarcoma necrosis rate after cisplatin chemotherapy.
本文旨在探讨骨肉瘤中 O(6)-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）的表达与烷化剂（顺铂，CDDP）疗效之间的相关性。共有 42 名男性和 34 名女性患者符合研究条件，中位年龄为 17 岁（9-43 岁）。根据组织病理学类型，有 3 例毛细血管扩张性成骨肉瘤、22 例成骨型、11 例软骨母细胞型和 16 例纤维母细胞型肉瘤。采用免疫组织化学方法检测 MGMT 蛋白的表达。探讨了 MGMT 表达与 CDDP 治疗骨肉瘤疗效的相关性。免疫组化染色显示，76 例骨肉瘤活检标本中，52 例（68%）为阳性，27 例（35%）为弱阳性，18 例（24%）为中度阳性，7 例（9%）为强阳性。不同肿瘤病理类型的 MGMT 表达无显著差异（p>0.5）。在 CDDP 化疗后，MGMT 表达阳性的病理标本中，坏死率如下：Ⅰ级，5 例（38%）；Ⅱ级，7 例（25%）；Ⅲ级，15 例（21%）；Ⅳ级，2 例（23%）。MGMT 蛋白表达阳性时骨肉瘤的坏死率较低，而 MGMT 表达水平较低时坏死率较高（p<0.01）。骨肉瘤组织中 MGMT 表达水平与顺铂化疗后骨肉瘤坏死率呈显著负相关。
